PubMed · 1995 · 58 citations · 0 references
PharmacyPharmaceuticsPharmacologyBioavailabilityBioequivalenceBiopharmaceuticsBioequivalence Study DesignComparative Dissolution TestingDrug DispositionDrug SolubilityIn Vitro Dissolution TestingDrug Product ComparisonDrug Solubility ScreeningHigh SolubilityHighly Soluble DrugsSilymarin TherapySolubility Determination
Seven silymarin products (pharmacies only), two of them with two batches each, were analysed for their ingredients, in particular silibinin (CAS 22888-70-6) and tested in vitro for their liberation of active agents. Founded on the results of these tests three products were checked for bioequivalence. Therefore, a typical phase I 3 fold crossover study was performed showing one product (Legalon) to be qualified by an approx. 2 fold higher silibinin availability compared to the two other preparations.